CervoMed Inc
CRVO
Company Profile
Business description
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Contact
20 Park Plaza
Suite 424
BostonMA02116
USAT: +1 617 744-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,201.50 | 16.00 | -0.17% |
| CAC 40 | 7,934.26 | 16.26 | 0.21% |
| DAX 40 | 24,387.93 | 146.47 | 0.60% |
| Dow JONES (US) | 46,067.58 | 587.98 | 1.29% |
| FTSE 100 | 9,442.87 | 66.53 | -0.70% |
| HKSE | 25,839.07 | 50.41 | -0.19% |
| NASDAQ | 22,694.61 | 490.18 | 2.21% |
| Nikkei 225 | 46,846.98 | 1,733.46 | -3.57% |
| NZX 50 Index | 13,276.99 | 74.93 | -0.56% |
| S&P 500 | 6,654.72 | 102.21 | 1.56% |
| S&P/ASX 200 | 8,891.00 | 18.70 | -0.21% |
| SSE Composite Index | 3,897.56 | 8.06 | 0.21% |